127 related articles for article (PubMed ID: 111586)
1. Titanocene dichloride--the first metallocene with cancerostatic activity.
Köpf H; Köpf-Maier P
Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
[No Abstract] [Full Text] [Related]
2. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
3. Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.
Köpf-Maier P; Hesse A
J Cancer Res Clin Oncol; 1984; 108(2):254-5. PubMed ID: 6540782
[TBL] [Abstract][Full Text] [Related]
4. [Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)].
Köpf-Maier P; Hesse B; Köpf H
J Cancer Res Clin Oncol; 1980 Jan; 96(1):43-51. PubMed ID: 7188941
[TBL] [Abstract][Full Text] [Related]
5. Antitumor metallocenes: new developments and toxicologic features.
Köpf-Maier P; Köpf H
Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
[TBL] [Abstract][Full Text] [Related]
6. Tumor inhibition by titanocene dichloride: first clues to the mechanism of action.
Köpf-Maier P; Köpf H
Naturwissenschaften; 1980 Aug; 67(8):415-6. PubMed ID: 7191057
[No Abstract] [Full Text] [Related]
7. [Histomorphologic changes in Jensen sarcoma following radiotherapy, titanocene dichloride treatment and combination therapy].
Uhl J; Langrock K; Krieghoff B; Hambsch K
Radiobiol Radiother (Berl); 1987; 28(1):51-7. PubMed ID: 3588859
[No Abstract] [Full Text] [Related]
8. Cytokinetic behavior of Ehrlich ascites tumor after in vivo treatment with cis-diamminedichloroplatinum(II) and metallocene dichlorides.
Köpf-Maier P; Wagner W; Liss E
J Cancer Res Clin Oncol; 1981; 102(1):21-30. PubMed ID: 7199526
[TBL] [Abstract][Full Text] [Related]
9. [Molybdocene dichloride as an antitumor agent (author's transl)].
Köpf-Maier P; Leitner M; Voigtländer R; Köpf H
Z Naturforsch C Biosci; 1979 Dec; 34(12):1174-6. PubMed ID: 161840
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of an ionic titanocene tetrachloroferrate derivative against some solid experimental tumors.
Köpf-Maier P; Klapötke T
Arzneimittelforschung; 1989 Apr; 39(4):488-90. PubMed ID: 2751735
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
12. Tumor inhibition by titanocene complexes: activity against sarcoma 180.
Köpf-Maier P; Preiss F; Marx T; Klapötke T; Köpf H
Anticancer Res; 1986; 6(1):33-7. PubMed ID: 3954328
[TBL] [Abstract][Full Text] [Related]
13. Micronucleated cells during the growth of the Ehrlich ascites tumour on spontaneous and by titanocenedichloride-induced conditions.
Tarillion P; Taubert G; Nenning H
Mutat Res; 1997 Mar; 389(2-3):213-8. PubMed ID: 9093386
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice.
Beckhove P; Oberschmidt O; Hanauske AR; Pampillón C; Schirrmacher V; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):311-5. PubMed ID: 17264764
[TBL] [Abstract][Full Text] [Related]
15. Pattern of toxicity by titanocene dichloride in mice: hematologic parameters.
Köpf-Maier P; Gerlach S
Anticancer Res; 1986; 6(2):235-40. PubMed ID: 3707061
[TBL] [Abstract][Full Text] [Related]
16. Activity of titanocene dihalides against a human colon carcinoma heterotransplanted to athymic mice.
Köpf-Maier P; Moormann A; Köpf H
Eur J Cancer Clin Oncol; 1985 Jul; 21(7):853-7. PubMed ID: 4043173
[TBL] [Abstract][Full Text] [Related]
17. The first organoantimony(III) compounds possessing antitumor properties: diphenylantimony(III) derivatives of dithiophosphorus ligands.
Silvestru C; Socaciu C; Bara A; Haiduc I
Anticancer Res; 1990; 10(3):803-4. PubMed ID: 2369094
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents.
Keller HJ; Keppler B; Schmähl D
Arzneimittelforschung; 1982; 32(8):806-7. PubMed ID: 6890355
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative activity of Titanocene Y against tumor colony-forming units.
Oberschmidt O; Hanauske AR; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):317-21. PubMed ID: 17264765
[TBL] [Abstract][Full Text] [Related]
20. Tumor inhibition by metallocenes: activity against leukemias and detection of the systemic effect.
Köpf-Maier P; Wagner W; Hesse B; Köpf H
Eur J Cancer (1965); 1981 Jun; 17(6):665-9. PubMed ID: 7308264
[No Abstract] [Full Text] [Related]
[Next] [New Search]